Combining PPARγ ligands such as rosiglitazone and GW1929 with the platinum-based drugs commonly used for lung cancer treatment, such as cisplatin and carboplatin, synergistically inhibits growth of multiple NSCLC cell lines [60]. This evidence concerns the gene PPARG and lung cancer.